(Q36968179)

17 August 2017

1 reference

title

The use of colesevelam hydrochloride in the treatment of dyslipidemia: a review (English)

1 reference

17 August 2017

1 reference

Michael H Davidson

1

1 reference

17 August 2017

language of work or name

English

0 references

publication date

1 October 2007

1 reference

Expert Opinion on Pharmacotherapy

17 August 2017

published in

1 reference

17 August 2017

volume

8

1 reference

17 August 2017

issue

15

1 reference

17 August 2017

page(s)

2569-2578

1 reference

Heart disease and stroke statistics--2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee

17 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.15.2569

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.15.2569

Clinical utility of bile acid sequestrants in the treatment of dyslipidemia: a scientific review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.15.2569

Effects of colesevelam HC1 on sterol and bile acid excretion in patients with type IIa hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.15.2569

Efficacy and safety of combination simvastatin and colesevelam in patients with primary hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.15.2569

Coadministration of colesevelam hydrochloride with atorvastatin lowers LDL cholesterol additively

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.15.2569

Safety and efficacy of colesevelam hydrochloride in combination with fenofibrate for the treatment of mixed hyperlipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.15.2569

Colesevelam HCl and ezetimibe combination therapy provides effective lipid-lowering in difficult-to-treat patients with hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.15.2569

The enzymes, regulation, and genetics of bile acid synthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.15.2569

Cholic acid mediates negative feedback regulation of bile acid synthesis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.15.2569

Nuclear receptor regulation of genes involved in bile acid metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.15.2569

Effects of colesevelam hydrochloride (WelChol) on biomarkers of inflammation in patients with mild hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.15.2569

Results of the glucose-lowering effect of WelChol study (GLOWS): a randomized, double-blind, placebo-controlled pilot study evaluating the effect of colesevelam hydrochloride on glycemic control in subjects with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.15.2569

Colesevelam: potential uses for the newest bile resin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.15.2569

Colesevelam hydrochloride: a non-absorbed, polymeric cholesterol-lowering agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.15.2569

Colesevelam hydrochloride in the management of dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.15.2569

AHA/ACC Guidelines for Secondary Prevention for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2006 Update

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.15.2569

10.1517/14656566.8.15.2569

21 January 2018

Identifiers

DOI

1 reference

17 August 2017

1 reference